MIT chemists synthesized a fungal compound that holds promise for treating brain cancer. Early studies find derivatives of the compound, verticillin A, can kill certain glioma cells.

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments. Conducted entirely at the University of Colorado Anschutz, this research has advanced from the laboratory to a Phase 1 clinical trial on the campus.

The findings, published today in Cancer Research Communications, outline a promising strategy that combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel therapy, SM08502, to attack cancer from two directions. This innovative approach boosts the effectiveness of the treatment, even for patients who are no longer responding to PARP inhibitor therapy. “This achievement exemplifies true bench-to-bedside innovation entirely done at CU Anschutz,” said the paper’s first author Bradley Corr, MD, associate professor and director of clinical research in gynecologic oncology at CU Anschutz. “To the best of our knowledge, this is the first clinical trial to successfully combine these classes of drugs. While the concept has been discussed before, no one has moved it into the clinic until now. That’s what makes this approach truly novel.”

The largest international gathering of breast cancer researchers returns to San Antonio and continues to lead as the hub for scientific breakthroughs. Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 48^th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 9-12.

A new study examined CRAFT-G, a remote group intervention combining cognitive training, psychoeducation, and occupational-therapy–based strategies for adults experiencing cancer-related cognitive impairment. The small pilot found high satisfaction, strong retention, and clinically meaningful improvements in daily functioning and self-perceived cognitive abilities among cancer survivors. The findings suggest that remote, group-based cognitive rehabilitation may offer an accessible and effective path to helping survivors manage “chemobrain” and reclaim everyday life.